Trial · NCT04649151
Participant flow90
How many started, completed or left each group, period by period.
41 to 60 of 90
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | Solicited Safety Set | Part 1A: mRNA-1273 100 μg | 2,485 | |
| Overall Study | Solicited Safety Set | Part 1A: Placebo | 1,240 | |
| Overall Study | Solicited Safety Set | Part 1C-2: mRNA-1273 50 μg Booster Dose (BD) | 125 | |
| Overall Study | Solicited Safety Set | Part 2: mRNA-1273 50 μg | 52 | |
| Overall Study | Solicited Safety Set | Part 3: mRNA-1273.222 50 µg | 387 | |
| Overall Study | PPIS | Part 1A: mRNA-1273 100 μg | 340 | |
| Overall Study | PPIS | Part 1A: Placebo | 0 | |
| Overall Study | PPIS | Part 1C-2: mRNA-1273 50 μg Booster Dose (BD) | 136 | |
| Overall Study | PPIS | Part 2: mRNA-1273 50 μg | 46 | |
| Overall Study | PPIS | Part 3: mRNA-1273.222 50 µg | 373 | |
| Overall Study | Per Protocol (PP) Set for Efficacy | Part 1A: mRNA-1273 100 μg | 2,142 | |
| Overall Study | Per Protocol (PP) Set for Efficacy | Part 1A: Placebo | 1,044 | |
| Overall Study | Per Protocol (PP) Set for Efficacy | Part 1C-2: mRNA-1273 50 μg Booster Dose (BD) | 0 | |
| Overall Study | Per Protocol (PP) Set for Efficacy | Part 2: mRNA-1273 50 μg | 0 | |
| Overall Study | Per Protocol (PP) Set for Efficacy | Part 3: mRNA-1273.222 50 µg | 0 | |
| Overall Study | Part 2 BD | Part 1A: mRNA-1273 100 μg | 0 | |
| Overall Study | Part 2 BD | Part 1A: Placebo | 0 | |
| Overall Study | Part 2 BD | Part 1C-2: mRNA-1273 50 μg Booster Dose (BD) | 0 | |
| Overall Study | Part 2 BD | Part 2: mRNA-1273 50 μg | 19 | |
| Overall Study | Part 2 BD | Part 3: mRNA-1273.222 50 µg | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04649151/flow?page=3